Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer

被引：0
|
作者：
Seong Yoon Yi
Young Suk Park
Hyo Song Kim
Hyun Jung Jun
Kyoung Ha Kim
Myung Hee Chang
Min Jae Park
Ji Eun Uhm
Jeeyun Lee
Se Hoon Park
Joon Oh Park
Jong Kyun Lee
Kyu Taek Lee
Ho Yeong Lim
Won Ki Kang
机构：
[1] Sungkyunkwan University School of Medicine,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine, Samsung Medical Center
来源：
Cancer Chemotherapy and Pharmacology | 2009年 / 63卷
关键词：
Pancreatic cancer; Irinotecan; Second line chemotherapy; Gemcitabine failure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1141 / 1145
页数：4
相关论文
共 50 条
  • [1] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Park, Y.
    Yi, S.
    Kim, H.
    Lee, S.
    Hwang, I.
    Park, S.
    Park, B.
    Park, J.
    Lim, H.
    Kang, W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [2] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Yi, Seong Yoon
    Park, Young Suk
    Kim, Hyo Song
    Jun, Hyun Jung
    Kim, Kyoung Ha
    Chang, Myung Hee
    Park, Min Jae
    Uhm, Ji Eun
    Lee, Jeeyun
    Park, Se Hoon
    Park, Joon Oh
    Lee, Jong Kyun
    Lee, Kyu Taek
    Lim, Ho Yeong
    Kang, Won Ki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (06) : 1141 - 1145
  • [3] Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
    Liuting Yang
    Xiaoyue Jiang
    Han Yan
    Yingying Li
    Hongchao Zhen
    Bingmei Chang
    Seyed Kariminia
    Qin Li
    [J]. BMC Gastroenterology, 18
  • [4] Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer
    Yang, Liuting
    Jiang, Xiaoyue
    Yan, Han
    Li, Yingying
    Zhen, Hongchao
    Chang, Bingmei
    Kariminia, Seyed
    Li, Qin
    [J]. BMC GASTROENTEROLOGY, 2018, 18
  • [5] Systematic review of benefits and risks of second-line irinotecan monotherapy for advanced colorectal cancer
    Oostendorp, Linda J. M.
    Stalmeier, Peep F.
    Pasker-de Jong, Pieternel C.
    Van der Graaf, Winette T.
    Ottevanger, Petronella B.
    [J]. ANTI-CANCER DRUGS, 2010, 21 (08) : 749 - 758
  • [6] Irinotecan as a Second-line Monotherapy for Small Cell Lung Cancer
    Sevinc, Alper
    Kalender, Mehmet Emin
    Altinbas, Mustafa
    Ozkan, Metin
    Dikilitas, Mustafa
    Camci, Celalettin
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2011, 12 (04) : 1055 - 1059
  • [7] Meta-analysis of irinotecan monotherapy versus irinotecan-based combined second-line therapy for the treatment of advanced gastric cancer
    Xu, Jia
    Zhang, Zi-Zhen
    Lin, Tian-Long
    Cao, Hui
    Yang, Han-Kwang
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (07): : 13712 - +
  • [8] S-1 Monotherapy as Second-line Treatment for Advanced Pancreatic Cancer after Gemcitabine Failure
    Todaka, Akiko
    Fukutomi, Akira
    Boku, Narikazu
    Onozawa, Yusuke
    Hironaka, Shuichi
    Yasui, Hirofumi
    Yamazaki, Kentaro
    Taku, Keisei
    Machida, Nozomu
    Sakamoto, Takeshi
    Tomita, Hideharu
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (06) : 567 - 572
  • [9] Single-agent irinotecan as second-line treatment for advanced gastric cancer
    Kanat, O
    Evrensel, T
    Manavoglu, O
    Demiray, M
    Kurt, E
    Gonullu, G
    Kiyici, M
    Arslan, M
    [J]. TUMORI JOURNAL, 2003, 89 (04): : 405 - 407
  • [10] Second-Line Treatment for Pancreatic Cancer
    Kaddis, Nancy
    Saif, Muhammad Wasif
    [J]. JOURNAL OF THE PANCREAS, 2014, 15 (04): : 344 - 347
12345